Power3 Buys Rozetta-Cell | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Power3 Medical Products today announced a definitive agreement to acquire all the stock of stem cell firm Rozetta-Cell Life Sciences.

Upon completion of the deal, expected in October or November, Rozetta-Cell will be merged with Power3 and take its name.

Terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.